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ABSTRACT 
Background: Social anxiety disorder (SAD) is a common mental disorder, causing 
considerable distress and functional disability for affected individuals and places a significant 
economic burden on society. However, few receive treatment due to several barriers such as 
low treatment availability, stigma and fear. The effectiveness of cognitive behavioural therapy 
(CBT) is well established, and recent innovations in e-health such as internet-based CBT 
(ICBT) may significantly increase access to effective care. Several trials have demonstrated 
that ICBT is both efficacious and cost-effective. However, before disseminating ICBT into the 
mental health care system, it is essential to evaluate its clinical effectiveness to study whether 
it works as expected when delivered as routine care in a naturalistic setting.  
Aims: The aims of this doctoral project were to evaluate the clinical effectiveness of ICBT in 
the treatment of SAD, to assess its non-inferiority against the standard treatment and to identify 
outcome predictors.  
Methods: Study I (N = 654), II (N = 446) and IV (N = 764) were longitudinal cohort studies 
of patients having been treated as part of routine care during 2009-2014. Within-group effects 
and the influence of potential predictor variables on treatment response and adherence were 
estimated using multilevel modelling. In Study III (N = 126), non-inferiority of ICBT was 
evaluated against standard treatment (face-to-face cognitive behavioural group therapy; 
CBGT) four years after treatment using a randomised controlled trial (RCT) design, assessing 
changes in symptoms of SAD and yearly societal costs. 
Results: In all studies, large (d = 0.8-1.3) improvements were observed after ICBT. Beneficial 
effects (i.e. reduced symptoms of social anxiety and co-morbid depressive symptoms and 
increased health-related quality of life) of treatment were maintained up to four years. When 
compared against standard treatment, ICBT was at least as long-term effective and cost-
effective; although the estimated treatment cost of ICBT amounted to only 17% of the cost of 
CBGT, both interventions were equally effective and led to similar yearly societal cost 
reductions. Improvement slopes varied significantly between patients. High levels of treatment 
credibility and adherence were associated with better treatment response. Furthermore, higher 
illness severity predicted greater improvement but was also related to worse follow-up status.  
Conclusion: ICBT can be successfully implemented in routine clinical care and is at least as 
effective and cost-effective as standard treatment for SAD, both short- and long-term. With its 
potential to significantly improve access to specialised mental healthcare, ICBT represents an 
important step forward in modernising healthcare systems through increased use of e-health. 
  
 SAMMANFATTNING 
Bakgrund: Socialt ångestsyndrom är en vanligt förekommande psykisk störning som orsakar 
ett betydande lidande och som för många kan bli väldigt handikappande. Då det är vanligt 
förekommande leder det även till betydande samhällsekonomiska konsekvenser. En stor andel 
av drabbade individer går utan behandling, dels på grund av låg tillgänglighet till effektiv 
behandling men kan även bero på stigma och rädsla för att söka vård. Nyttan av kognitiv 
beteendeterapi (KBT) är väl etablerad, och nya innovationer inom e-hälsa såsom 
internetförmedlad KBT (IKBT) kan avsevärt öka tillgången till effektiv vård. Flera 
kontrollerade studier har visat att IKBT är både effektiv och kostnadseffektiv. Innan vidare 
spridning av IKBT inom den psykiatriska vården är det däremot viktigt att utvärdera dess 
kliniska effektivitet för att undersöka om behandlingsformatet fungerar som förväntat när det 
ges som reguljär behandling i en naturlig vårdmiljö. 
Mål: Syftet med detta doktorandprojekt var att utvärdera den kliniska effektiviteten av IKBT 
vid behandling av socialt ångestsyndrom, att bedöma om den är minst lika verksam och 
kostnadseffektiv som standardbehandling samt att identifiera faktorer som kan förklara 
variationen i behandlingsresultat. 
Metoder: Delstudie I (N = 654), II (N =446) och IV (N = 764) var longitudinella kohortstudier 
av patienter som behandlats som en del av reguljär vård under 2009-2014. Inomgruppseffekter 
och påverkan av potentiella utfallsprediktorer uppskattades med hjälp av flernivåanalys. I 
delstudie III (N = 126) utvärderades IKBT mot standardbehandling (KBT i grupp) fyra år efter 
avslutad behandling i form av en randomiserad kontrollerad studie. Förändringar i symptom på 
social ångest samt årliga samhällskostnader beräknades.  
Resultat: I samtliga studier kunde stora (d = 0,8-1,3) förbättringar observeras efter 
genomgången IKBT. Uppnådda behandlingsresultat bibehölls i upp till fyra år, både när det 
gäller minskning av symtom på social ångest, depressiva symptom och hälsorelaterad 
livskvalitet. Vid jämförelse mot standardbehandling var IKBT var minst lika effektiv och 
kostnadseffektiv på lång sikt; trots att den uppskattade behandlingskostnaden för IKBT endast 
utgjorde 17% av kostnaden för standardbehandling var behandlingarna lika effektiva och ledde 
till liknande samhällsbesparingar. Det fanns tydliga skillnader i behandlingssvar mellan 
patienter. Hög grad av följsamhet samt hög upplevd trovärdighet av IKBT var associerat med 
bättre behandlingssvar. Dessutom var sjukdomens svårighetsgrad relaterad till 
behandlingssvar: högre sjukdomsgrad ledde till snabbare förbättring, dock var sjukdomsnivån 
också högre vid uppföljning.  
Slutsats: IKBT kan framgångsrikt implementeras i reguljär klinisk vård och är minst lika 
effektiv och kostnadseffektiv som standardbehandling för behandling av socialt 
ångestsyndrom, både på kort och lång sikt. Då IKBT har en betydande potential att avsevärt 
förbättra tillgången till specialiserad psykiatrisk vård utgör behandlingen ett viktigt steg framåt 
för att modernisera hälso- och sjukvårdssystemen genom ökad användning av e-hälsa inom 
vården.  
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1 INTRODUCTION 
1.1 MENTAL ILL-HEALTH IS A RISING CONCERN 
Mental ill-health is one of the leading causes of disability worldwide (1), and approximately 
40% of the population will at some point during their life need professional help for clinical 
anxiety or depression (2). Anxiety disorders are the most prevalent class of mental disorders 
(3), and among these, social anxiety disorder (SAD) is considered to be the most common (4, 
5) with a 12-month prevalence in the range of 2.8%-7.1% and a lifetime prevalence of 5%-
12.1% (6-8).i At the core of SAD is a fear of being scrutinized and negatively judged by others 
and act in a way that is embarrassing and humiliating. Affected individuals therefore tend to 
avoid feared social or performance situations, experience anxious anticipation of these or 
intense anxiety in them, to such a degree that problematic thoughts, behaviours and feelings 
interfere with their daily lives, occupational or academic functioning or with their social 
relationships (10).ii Many – about half of affected individuals in developed countries (6) – do 
not receive treatment. A central barrier to appropriate mental health care is low availability of 
trained personnel to deliver effective treatments (12, 13). As a result, there are significant 
personal (14) and societal (15) economic consequences.iii There have been attempts to estimate 
the costs of SAD. Such health economic evaluations are often performed from a societal 
perspective, meaning that in addition to healthcare costs, indirect costs such as sick-leave and 
productivity losses are also considered (15). In a study of individuals with SAD in the general 
population, it was estimated that the average annual societal cost was approximately €12 000 
per person. This can be compared with an estimated annual cost of about €3 000 for non-
affected individuals (15).  
Considering the rising concern of mental ill-health, with yearly costs of over EUR 7 billion 
only in Sweden (17) due to lost productivity, healthcare consumption and social benefits, a 
major challenge for mental healthcare is to meet the growing need to treat and prevent mental 
illness in order to include as many as possible within the labour market. 
                                                 
i Different rates reported between studies likely depend on different methodological approaches when diagnosing 
SAD (e.g. the specific threshold for disability) (4). Defining SAD depending on the degree of distress required has 
yielded similar variations in estimated prevalence rates, ranging between 1.9% and 15.6%, in a Swedish study (9). 
ii When seeking treatment, patients are asked to describe their symptoms and how these affect their lives. Until 
recently, it was the patient who would determine whether their fears were rational, but as of DSM-5 it is now the 
clinician who determines whether the fears being described are proportionate in relation to the risk or consequences 
of negative evaluation (11). A further change in the updated diagnostic manual is the broadening of possible feared 
consequences as they now also include a fear of rejection or offending others in addition to the fear of being 
humiliated and embarrassed (11). 
iii It has been estimated that the cumulative global economic loss due to mental disorders will amount to US$ 16.3 
trillion between 2011 and 2030 (16). In Europe, the costs of mental disorders account for approximately 3.5% of 
GDP (17). 
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1.2 TREATMENT OF SOCIAL ANXIETY DISORDER 
As for SAD, short-term symptom reduction can effectively be achieved with pharmacological 
therapy using Selective Serotonin Re-Uptake Inhibitors (SSRIs) (18).iv However, although a 
range of pharmacological treatments have been tested, many of these have reported negative 
side effects that may be considered unsafe or lead to physical dependence (19, 20). Instead, 
most individuals prefer psychological treatments (21). Cognitive behavioural therapy (CBT) – 
a problem focused and highly action oriented intervention – is not only considered as an 
alternative for those not responding to pharmacological therapy (18) but with its strong 
empirical support (22), CBT is gaining recognition as a first line treatment for SAD (23). CBT 
has a strong emphasis on modifying everyday behaviour and challenging the validity of 
maladaptive negative thoughts. Hence, CBT targets behaviours, emotions and cognitions – 
factors that are maintaining the disorder – through a collection of techniques such as 
psychoeducation, cognitive restructuring, exposure to feared situations and relapse prevention 
(22, 24). Effect sizes of CBT for SAD have been reported in the range of d = 0.70 (25) to d = 
0.86 (26). A meta-analysis covering 21 trials found that the average treatment effect was d = 
0.83 (27). When estimating the average effect of only those studies that used a control group, 
a meta-analysis of 16 trials yielded an average d of 0.74 (28). Thus, the effects tend to range 
between moderate to large, according to the commonly used threshold values proposed by 
Cohen v. CBT in group format (CBGT) seems to have the best empirical support with superior 
effects compared with for example treatment as usual (30), other psychological treatments (31), 
fluoxetine or pill placebo (32).  
Despite the substantial evidence (33-35) of the effectiveness of CBT, there are several barriers 
to treatment, primarily the limited availability of trained therapists. There is also evidence that 
most people with SAD do not seek treatment (36). The very nature of SAD with its disorder-
specific fear of social interaction may partially explain this avoidance (37). There may also be 
the issue of stigma associated with undergoing psychotherapy. Further, there are practical 
barriers such as difficulties accessing treatment due to remote locations for people living in 
                                                 
iv SSRIs are antidepressant medications that have both an anxiety reducing effect and that can also treat depressive 
symptoms. These effects are achieved by manipulating the activity of the brain chemicals serotonin and/or 
noradrenaline. SSRIs have several benefits when compared with benzodiazepines and are considered to be the 
first-line pharmacological treatment for SAD today due to its moderate effect sizes and favourable side-effect 
profile (18). Besides alleviating both anxiety and co-morbid depression, they do not cause dependence in the same 
way as benzodiazepines (although a withdrawal state can be experienced if discontinuation is not managed 
gradually) and can be used for long-term treatment. The disadvantages are mainly that patients may experience an 
initial increase in anxiety when starting treatment, and – as is generally the case with pharmacological treatment 
of mental disorders – there is a significant risk that symptoms of social anxiety will return when the medical 
intervention is discontinued. 
v A statistical method of arriving at such a description is the calculation of Cohen’s d which standardizes the 
difference between two means and compare it to 0. This difference is expressed in standard deviation units, which 
can be interpreted as small (0.2 of a standard deviation), moderate (0.5 of a standard deviation) or large (0.8 of a 
standard deviation) (29). As such, it provides a way of quantifying the effect of an intervention, comparable across 
studies using the same effect measure. 
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rural areas, long waiting lists, limited clinic opening hours, and also the cost associated with 
treatment. 
Hence, there is a need for innovative solutions that may facilitate treatment seeking, increase 
access to effective treatment and also increase the capacity of healthcare providers to deliver 
treatment to more individuals (38, 39).  
1.3 INTERNET-BASED COGNITIVE BEHAVIOURAL THERAPY 
1.3.1 Improving healthcare delivery 
With the emergence of e-health and internet interventions such as internet-based CBT (ICBT), 
most of the above mentioned barriers to effective care can potentially be overcome and the 
threshold for seeking help may be lowered (40). Since information technology is fundamentally 
altering not only the way societies work at large and how we communicate, its application 
within healthcare is also significantly changing and modernising the way patients interact with 
healthcare providers. Indeed, e-health is increasingly becoming recognised as the most 
promising approach to improve the quality of care, patient safety and the efficiency of 
healthcare delivery (41). As awareness of ICBT increases among healthcare providers, it is 
gaining interest as a new method of treatment delivery that could use limited therapist resources 
in a more efficient way and consequently increase access to effective psychological treatments 
within mental healthcare (42). The intervention itself is similar to standard treatment (i.e. face-
to-face CBT) including methodology and core components such as education about social 
anxiety, safety-seeking behaviours, cognitive restructuring, behavioural experiments, exposure 
to feared situations, attention training and relapse prevention, with the major difference being 
the form of communication and the time used for therapist support (43). From a health 
economic perspective, an central benefit of ICBT, therefore, is its potential cost-effectiveness 
(44, 45) compared to conventional individual face-to-face psychotherapy, mainly because it 
requires less therapist time (42, 46, 47). 
1.3.2 Efficacy and outcome predictors 
Several independent research groups have studied ICBT for SAD to evaluate its efficacy in a 
number of controlled trials, and the results are promising (43, 48-56). Evidence suggest that 
ICBT is as efficacious as conventional face-to-face CBT, not only for SAD but for a wide range 
of mental disorders (34, 57, 58), and significant long-term effects of ICBT for SAD have been 
demonstrated for up to five years after treatment (59-61).  
Attempts have also been made to identify patient characteristics that are associated with 
treatment outcome using predictive analytics. More knowledge of outcome predictors may help 
determine whether ICBT is likely to benefit all or only some individuals, and identify factors 
that may explain the significant variation in treatment response between patients. An important 
question is whether ICBT is suitable also for more severe cases, or whether they would benefit 
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more from high-intensity face-to-face therapy. Another question concerns the influence of co-
morbidity (e.g. depressive symptoms) on treatment outcome. Although findings have not been 
consistent across studies, there are some interesting observations on the role of illness severity, 
co-morbid depressive symptoms and outcome vi that have been reported. For example, the level 
of symptom severity at baseline is typically related to the degree of severity at post-treatment 
(62, 63), although this association is less clear in regard to symptomatic change (64, 65). The 
role of co-morbid depressive symptoms has not been consistently determined across studies; 
evidence from both CBT (63, 66) and ICBT (67) have found co-morbid depressive symptoms 
to be related to worse outcome, whereas other reports of ICBT found no such relation (68). A 
recent study using a different analytical approach was able to provide an explanation of the 
seemingly contradictory results reported in the previous literature. By focusing on social 
avoidance and comorbid depressive symptoms, subgroups of patients having different degrees 
of a combination of these two risk factors were identified by using cluster analysis. It was found 
that just having a higher levels of co-morbid depressive symptoms was not a risk-factor of poor 
treatment outcome in itself, but rather its combination with also having a high level of social 
avoidance (69). Finally, there is also evidence that the perceived credibility of ICBT (67, 68) 
and the level of treatment adherence (52, 67, 68, 70-72) are positively associated with treatment 
outcome. Consequently, expecting the treatment to work may be a critical success factor, and 
there seems to be a clear dose-response relationship suggesting that the more of the treatment 
content that patients are exposed to the more they are likely to benefit. 
1.3.3 Clinical effectiveness 
Although the efficacy of ICBT for SAD has been demonstrated in numerous trials, clinical 
effectiveness studies within the context of regular care that aim to maximize external validity 
is an important element of clinical research (73). Accordingly, in order to see whether the 
results of RCTs can be generalized to patients within regular care, this doctoral project arose 
from the need to thoroughly evaluate the use of ICBT as a method of treatment delivery in 
clinical day-to-day practice. Since many patients do not achieve sufficient symptomatic 
improvement after ICBT (74), such an evaluation would also include the identification of 
variables associated with treatment response, as predicting the likely course of symptomatic 
change for different subgroups of patients might enable clinicians to provide more 
individualised care to meet different patient needs.  
Knowledge of the clinical effectiveness of ICBT for SAD has been lacking and is important 
before dissemination within the public mental healthcare system. This thesis presents four 
studies that explore the clinical effectiveness of ICBT for SAD over the years that the treatment 
has been implemented as routine care at the Internet Psychiatry Clinic, Psychiatric Clinic 
Southwest at Karolinska University Hospital Huddinge, Sweden. 
                                                 
vi The operational definition of outcome may differ between studies, and may refer to either achieved end state 
(i.e. the level of symptoms after treatment) or observed change between pre- and post-treatment. 
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1.4 AIMS OF THE DOCTORAL PROJECT 
The overall aim of this research was to evaluate whether ICBT can be successfully 
implemented in routine clinical care as an effective method of treatment delivery, and 
consequently whether it can be safely recommended for dissemination within the public 
healthcare system. Although this research has implications for the treatment of a broader range 
of psychiatric disorders, the focus of this investigation has been on evaluating the treatment of 
SAD. The specific aims of each study in this thesis are presented below. 
1.4.1 Study I 
The aim of Study I was to evaluate ICBT for SAD when implemented as routine care. That is, 
to validate its clinical effectiveness in a naturalistic setting. This evaluation would also include 
a comparison of the magnitude of treatment results over the years that the ICBT unit has 
operated. 
1.4.2 Study II 
The primary aim of study II was to evaluate the sustainability of treatment effects achieved 
after ICBT for SAD, and secondly to identify factors that influence long-term improvement.  
1.4.3 Study III 
The aim of Study III was to evaluate whether ICBT for SAD is at least as long-term effective 
and cost-effective as the standard treatment.  
1.4.4 Study IV 
The aim of Study IV was to identify factors that may explain differences in symptomatic 
improvement and treatment adherence.  
  7 
2 METHODS 
2.1 SETTING AND PARTICIPANTS 
All of the studies were conducted at the Internet Psychiatry Clinic, Psychiatric Clinic Southwest 
at Karolinska University Hospital Huddinge, Stockholm, Sweden. Irrespective of whether 
patients were self-referred or referred by a general practitioner, they had to first register for 
treatment online through a public e-service portal for healthcare (i.e. Healthcare Guide 1177, 
formerly known as “Mina Vårdkontakter”). At the time of the studies, only patients that were 
residents in Stockholm County could register.vii A structured diagnostic interview with a 
clinician was required before treatment. Therefore, all patients who completed the online 
screening procedure were invited to the ICBT unit for a clinical visit. Besides meeting the 
DSM-IV criteria for SAD, a more general prerequisite for treatment inclusion was having a 
basic capability to assimilate the content of the treatment; since ICBT is highly dependent on 
patients’ abilities to access, read and use web-based material on their own, having a minimum 
level of computer literacy and being able to read and write in Swedish was necessary.  
Of those who completed the initial online screening for routine care (i.e. Studies I, II and IV), 
approximately 60% were included for treatment. There were several reasons reported by the 
medical staff for excluding patients after the initial clinical visit, the three most common being 
that the patient did not fulfil the diagnostic criteria for SAD or that SAD was not their primary 
diagnosis (around 30% of excluded patients), that patients themselves decided not to initiate 
the treatment (around 20%) or that the ICBT treatment format was considered to be suboptimal 
considering the level of clinical complexity (e.g. severe cases with high degree of comorbidity, 
around 15%). Less common reasons for exclusion, with occurrences in the range of around 2-
4%, were for example substance misuse, moderate to high suicide risk, language difficulties or 
not attending the clinical visit. Sample sizes of patients included in Studies I-IV are 
summarized in Table 1 along with data on assessment completion. 
 
Table 1. Study participants. 
Study Sample (N) Provided follow-up data, N (% of included patients) 
  Post-treatment 6-month follow-up Long-term follow-up 
Study I 654 547 (84%) 172 (42%)  
Study II 446 391 (88%) 173 (39%) 321 (72%) 
Study III 126 125 (99%) 119 (94%) 103 (82%) 
Study IV 764 657 (86%)   
                                                 
vii As of January 2015, a new patient law has made it possible also for patients residing outside of Stockholm 
County to register for treatment at the Internet Psychiatry Clinic. 
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In Studies I, II and IV, cohorts with available clinical data at the time of extraction were 
examined. Consequently, the differences in sample sizes between the studies shown in Table 1 
reflects that somewhat different time periods were examined (e.g. Study IV was performed at 
a later point in time than Study I, when more patients had been treated at the clinic). Study II 
included only 446 patients since not all patients had fulfilled criteria for inclusion to follow-up 
data collection (i.e. they had to have completed treatment approximately one year earlier). 
These patients were thus invited to complete a follow-up assessment 1-4 years after treatment 
(M = 2.66 yrs., SD = 0.80). In Study III, out of 230 referred patients, 126 had met inclusion 
criteria and were included in the original RCT (53) and allocated to either ICBT (n = 64) or to 
GCBT (n = 62). The recruitment process is described in the original article (53). In the long-
term follow-up study (i.e. Study III), these patients were contacted four years (M = 4.2 yrs., SD 
= 0.7) after treatment and were asked to complete self-report assessments online. Of the 126 
participants included, 103 (82%) completed long-term follow-up assessments. 
2.2 STUDY DESIGN 
Although Study III was a follow-up of a previously conducted RCT, its purpose was to evaluate 
ICBT against standard treatment within a clinical setting. Studies I, II and IV were exclusively 
focused on examining how ICBT works after the treatment had been implemented as routine 
care.viii As such, these were characterised by a more naturalistic design, following large cohorts 
of patients over several years applying a methodological approach which concerned the 
exploration of patterns of symptomatic change over time. Also, since these were longitudinal 
cohort studies of registry-type data with no comparison group or randomization procedure 
involved, Study III therefore complemented Studies I, II and IV due to its controlled design.  
2.3 OUTCOME MEASURES 
The primary outcome measure was the self-report version of the Liebowitz Social Anxiety 
Scale (LSAS-SR) (75). Remission was operationalised as achieving a cut-off score of LSAS-
SR ≤ 30, indicative of probable absence from social anxiety disorder (76). Secondary outcomes 
were co-morbid depressive symptoms and health-related quality of life. These were measured 
using the self-rated Montgomery-Åsberg Depression Rating Scale (MADRS-S) (77) and the 
EQ-5D (78). In addition, the level of treatment adherence, operationalised as the number of 
accessed treatment modules between pre- and post-treatment, was examined as an outcome 
predictor in Study I and as a dependent variable in Study IV.  
                                                 
viii Although the clinical setting was the same across all studies, the non-inferiority trial had somewhat stricter 
inclusion criteria. For example, not scoring > 20 on the MADRS-S was a criterion in the RCT (53), which can be 
compared with the significantly higher exclusion threshold of ≥ 35 on the MADRS-S when the treatment was 
offered as routine care. The mean pre-treatment level of depressive symptoms was 12.7 (SD = 6.5) in the RCT and 
14.7 (SD = 7.5) in Study I. 
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2.4 ASSESSMENTS 
Consistent with the operational routines at the ICBT unit, patients provided online self-
assessments at the following occasions: at screening, at treatment start (pre-treatment), weekly 
during treatment, at the end of treatment (post-treatment) and finally at six months after 
treatment (6MFU). In addition, clinician-administered assessments were completed for all 
patients prior to treatment and patients were also invited to a follow-up visit after treatment. 
The screening procedure included the following set of online instruments: an initial assessment 
of the medical history adapted from The Structured Clinical Interview for DSM-IV Axis I 
Disorders (SCID-I), the LSAS-SR, the MADRS-S, the EQ-5D, the Alcohol Use Disorders 
Identification Test (AUDIT) (79, 80), the Drug Use Disorder Identification Test (DUDIT) (80-
82), a questionnaire on healthcare consumption and productivity losses for patients with a 
psychiatric disorder (TIC-P) (83) and the World Health Organization Adult ADHD Self-Report 
Scale (ASRS) Screener (84). Additional information was collected by the medical doctor 
during the clinical visit including clinician-ratings of the LSAS and the MADRS. A structured 
diagnostic interview was also conducted using the Mini International Diagnostic Interview 
(MINI; 85).  
2.5 STATISTICAL ANALYSES 
A common analytic theme throughout the studies were the use of multilevel models, a relatively 
advanced type of regression analysis, to examine symptomatic change over time. To illustrate 
the relative complexity of the observations to be examined in Studies I, II and IV, Figure 1 
shows the symptomatic patterns of change for a random selection of 100 patients. As can be 
seen, there are large variations in both initial symptom severity and in how the level of social 
anxiety changes over time.  
 
Figure 1. Observed symptomatic change over time for a random sample. 
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Multilevel modelling is particularly suitable for this type of longitudinal data with repeated 
measurements because the information is typically organised in more than one level (i.e. the 
data is hierarchical ix) and missing values is often an issue (86). Because observations are 
analysed on an intention-to-treat (ITT) basis, all patients are included in the analyses 
irrespective of how many measurements they have provided or whether they have dropped out 
before post-treatment assessment. As such, multilevel models use all available data, regardless 
of whether measurements are missing on some occasions. This is an advantage compared with 
traditional regression methods or analysis of variance (ANOVA), where cases that have 
missing data are typically deleted from the analysis (i.e. complete case analysis).x Another 
advantage is that the hierarchical structure of the data is accounted for in the computations of 
the estimates. This aggregated nature of the data is important to consider because it can affect 
the reliability of the results.  
A multilevel approach was also applied when evaluating the influence of different variables on 
the regression slopes, that is, how they affect the rate of improvement. By using data collected 
during screening and during the clinical visit, a relatively large number of potential predictor 
variables could be explored. To systematically examine these predictors, we followed the 
procedure adopted by Fournier et al. (87) and Amir et al. (88) in which the variables were first 
screened for their prognostic value by analysing them in separate domains (socio-demographic 
variables, clinical characteristics, family history of mental illness and treatment-related factors) 
before including them into a final model containing only those variables who had a significant 
effect at the p < .05 level within each respective domain. Thus, in the final model, the effect of 
each predictor was estimated while controlling for the effects of the other predictors.  
2.6 COST-EFFECTIVENESS 
Since public health resources are limited, choices need to be made about how these should be 
allocated to provide the most benefit. Evaluating the relative cost-effectiveness of different 
interventions (e.g. between ICBT and standard treatment) is a way to guide such decisions, as 
a cost-effectiveness analysis (CEA) can estimate the likely benefits and costs of an intervention 
relative to the alternative (89). In Study III, one objective was to estimate the long-term cost-
effectiveness of ICBT. Given the significant amount of indirect costs associated with SAD 
(90), a societal perspective was adopted to evaluate societal economic gains achieved through 
ICBT (15). The main outcome of the CEA was the incremental cost-effectiveness ratio (ICER) 
which is the ratio of the costs to the health effects between ICBT and CBGT (89). The ICER, 
therefore, is an estimation of the additional cost for each treatment responder or for each quality 
                                                 
ix Since each patient provides several measurements over time, these data are organized at several levels. For 
example, each set of repeated LSAS-SR scores (Level 1) are related to a specific patient (Level 2). 
x Imputation of missing values is also an option in these cases. 
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adjusted life year (QALY) gained. Visually, the ICER can be illustrated using the cost-
effectiveness plane (91). This plane (Figure 2) can be divided into four quadrants, each having 
a different implication for the economic evaluation of the intervention and consequently for 
decision makers. ICERs located in the south-east quadrant implies that the intervention is more 
effective while less costly than the alternative, thereby always considered as cost-effective. At 
the opposite end, in the north-east quadrant, the costs and effects are all worse than the 
alternative (i.e. more costly and less effective). In such a scenario, the intervention can never 
be considered as cost-effective. Finally, in the north-east and south-west quadrants, the cost-
effectiveness depends on the willingness to pay (WTP) xi for each responder or for each QALY 
gained. In Figure 2, the slope of the line between the standard treatment (at the centre of the 
diagram) and the ICBT point estimate indicates the cost-effectiveness ratio. Since the cost-
effectiveness ratio is the slope that extends from the origin (which is the treatment option that 
ICBT is being compared with) to an estimated cost-effect combination of the ICBT option, we 
can see that the cost-effectiveness of ICBT is always evaluated against an alternative. Thus, in 
a CEA, a treatment can never be cost-effective in itself, only in relation to another treatment 
option and to the willingness to pay (illustrated as the dashed line in Figure 2).  
 
  
                                                 
xi As guidelines for what might be regarded as good value for money, there are frequently used thresholds of the 
WTP for health effects, also known as the maximum acceptable ceiling ratio (92). These tend to vary between 
countries. For example, the National Institute for Health and Clinical Excellence (NICE) in the UK values the cost 
per QALY at £20 000-£30 000 (€22 000-€34 000; $30 000-$45 000) and in the USA, this threshold is typically 
$50 000 per QALY. If a treatment costs less that the threshold value, the treatment is typically considered cost-
effective. 
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Figure 2. The cost-effectiveness plane. Adapted from Black (1990). 
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There will always be some degree of uncertainty around the estimated ICERs (93). In Study 
III, this uncertainty was reported both as a confidence interval (CI) around the estimate and 
also graphically as a cost-effectiveness acceptability curve (CEAC). Also, a cost-effectiveness 
plane was presented as a scatter plot xii of a large number of mean differences in costs and 
effects to provide an illustration of the uncertainty surrounding the estimated difference in cost 
and effect of ICBT compared to the alternative. 
2.7 ETHICAL CONSIDERATIONS 
All studies were approved by the Regional Ethical Review Board in Stockholm, Sweden. The 
risks of this research has been considered to be relatively small compared to the potential 
benefits. Written informed consent was obtained from all participants in Study III. Studies I, II 
and IV were retrospective cohort studies; participants were thus informed about the research 
and given the choice of participation through an opt-out methodology. This is generally 
considered to be the most efficient procedure for using registry data, an approach that increases 
the likelihood of having a more representative sample (94) while not violating the option of 
providing choice (95). For increased protection of privacy during internet communications, 
data traffic was secured using 128-bit Secure Sockets Layer (SSL) encryption, which 
corresponds to the same level of protection commonly used by banks for financial transactions. 
Further, patients logged into the treatment system via the public healthcare portal (Mina 
Vårdkontakter), which applied a log-in procedure in accordance with The National Board of 
Health and Welfare (Socialstyrelsen) and The Swedish Data Protection Authority 
(Datainspektionen) regulations.   
                                                 
xii 5000 ICERs were generated using nonparametric bootstrapping. 
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3 RESULTS 
This chapter presents the results of the Studies. The following chapter will then discuss these 
findings within the context of the literature and their implications. 
3.1 SUBJECTS 
The mean age was around 33 years and the gender distribution was approximately 55% 
females. About half of the subjects were married or living in a relationship. The educational 
level was relatively high, with about 60% of patients having university level studies. Most 
patients (approximately 90%) were self-referred. About 50% were working full-time, 8% were 
unemployed and students constituted a significant proportion (22%). 
3.2 STUDY I 
Effectiveness of Internet-Based Cognitive-Behaviour Therapy for Social Anxiety 
Disorder in Clinical Psychiatry 
Large reductions in social anxiety after treatment (effect size d = 0.86) with sustained 
improvements at 6-month follow-up (d = 1.15) were observed (Figure 3). Although only 20% 
of patients had achieved remission (LSAS-SR ≤ 30) immediately after treatment, this figure 
had increased to 36% at 6-month follow-up, suggesting that patients continued to improve after 
the therapist-guided treatment phase of 12 weeks.  
 
Figure 3. Estimated change in social anxiety and co-morbid depressive symptoms. Abbreviations: LSAS-SR, 
Liebowitz Social Anxiety Scale-Self-report; MADRS–S, Montgomery-Åsberg Depression Rating Scale–Self-Report. 
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A yearly increase in the rate of improvement was also observed (see Figure 3 in the published 
article); three years after treatment implementation, the average LSAS-SR post-treatment score 
was about 16 points below the estimated end point score during the first year. In addition, the 
level of treatment adherence was related to the rate of improvement (i.e. the more modules 
patients completed, the more they benefited from the treatment).  
Co-morbid depressive symptoms were significantly improved after treatment, with a moderate 
pre-post effect size of d = 0.56 (Figure 3). Noteworthy is the significant spontaneous 
improvement observed between screening and start of treatment (a waiting-time of 
approximately 2-3 weeks), corresponding to a moderate effect size of d = 0.57, which was 
similar to the degree of improvement achieved during treatment. Finally, the average level of 
satisfaction with the treatment was about 80%. 
3.3 STUDY II 
Long-term Effectiveness and Outcome Predictors of Therapist-guided Internet-based 
Cognitive-behavioural Therapy for Social Anxiety Disorder in Routine Psychiatric Care 
Long-term improvements in both social anxiety (d = 1.17) and co-morbid depressive symptoms 
(d = 0.67) were observed up to four years after treatment (Figure 4). Although most of these 
improvements were achieved during treatment, patients continued to improve for up to four 
years after treatment.  
 
Figure 4. Long-term course of improvement in social anxiety and depressive symptoms after internet-based 
cognitive behavioural therapy in routine care. Abbreviations: LSAS-SR, Liebowitz Social Anxiety Scale-Self-report; 
MADRS–S, Montgomery-Åsberg Depression Rating Scale–Self-Report. 
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Patients also improved in health-related quality of life (d = -0.25) (Figure 5). 
 
Figure 5. Long-term course of improvement in quality of life after internet-based cognitive behavioural therapy 
in routine care. Abbreviations: EQ-5D, EuoroQol five dimensions. 
 
Finally, the rate of long-term symptomatic change varied significantly between individuals. A 
faster rate of improvement was observed among patients having a higher illness severity at 
baseline. Further, a slower rate of improvement was observed among those who reported 
having a family history of social anxiety. 
3.4 STUDY III 
Clinical Effectiveness and Cost-effectiveness of Internet- vs. Group-based Cognitive 
Behaviour Therapy for Social Anxiety Disorder: 4-Year Follow-up of a Randomized 
Trial 
Large improvements (d = 1.34–1.48) were observed at 4-year follow-up on the primary 
outcome measure (LSAS-SR) in both ICBT and standard treatment (CBGT), differing only 
within the equivalence margin.  
The CEA indicated that both treatments were equally cost-effective four years after treatment, 
which is reflected in the estimated probability of 62% that ICBT is a cost-effective treatment 
long term relative to CBGT at a WTP $0 for one additional QALY, marginally increasing to 
64% at a WTP of $100 000. Specifically, both treatments were equally effective in terms of 
health improvements and similar reductions in indirect costs were observed. Societal gains 
were primarily caused by lower costs of unemployment. Total costs in both conditions were 
reduced by approximately half compared to pre-treatment (Figure 6).  
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Figure 6. Total Cost of ICBT and standard treatment (CBGT). Net total costs include interventions costs. 
Abbreviations: ICBT, Internet-based cognitive behaviour therapy; CBGT, Cognitive behavioural group therapy; 
Pre, before treatment; 4YFU, four years after treatment.  
3.5 STUDY IV 
Predictors of Symptomatic Change and Adherence in Internet-Based Cognitive 
Behaviour Therapy for Social Anxiety Disorder in Routine Psychiatric Care 
Results from Study IV indicate that the two most important factors that were associated with a 
faster rate of improvement (i.e. a steeper slope of the linear regression line) during treatment 
were treatment credibility (patients’ beliefs and expectations about the treatment) and the level 
of adherence (number of accessed modules). In addition, a slower rate of improvement (i.e. a 
flatter slope) was observed among patients having a higher overall functioning level at baseline. 
The amount of therapist time spent was also negatively associated with outcome. 
Having a family history of social anxiety was associated with greater treatment adherence, 
whereas having ADHD-like symptoms, being male, and having a family history of minor 
depression were related to a somewhat lower level of adherence.  
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4 CONCLUSIONS AND IMPLICATIONS 
The overall aim of this research was to evaluate ICBT for SAD when implemented in routine 
outpatient care. The specific aims of each study was to: 
 Validate the clinical effectiveness of ICBT for SAD in a naturalistic setting. 
 Assess the long-term effectiveness of ICBT for SAD and identify long-term outcome 
predictors.  
 Evaluate whether ICBT for SAD is at least as long-term effective and cost-effective as 
standard treatment. 
 Identify factors that are related to sympomatic change and treatment adherence. 
We will now turn to a discussion of the implications of the findings and discuss some 
limitations of the studies. Finally, some avenues for further research are suggested.  
4.1 CONCLUSIONS ABOUT EACH RESEARCH QUESTION 
4.1.1 ICBT can be successfully implemented in routine clinical care 
As was indicated in the introduction, there has been a knowledge gap in regard to the clinical 
effectiveness of ICBT for SAD. Results from Study I suggest that ICBT for SAD is clinically 
effective and can be successfully implemented in routine outpatient psychiatric care. Further, 
the collective evidence from the studies in this thesis, coupled with two recent effectiveness 
studies conducted in Australia (96, 97) – also having relatively large patient samples –provide 
a good basis on which to establish the clinical effectiveness of ICBT for SAD by independent 
research groups. The recently published Australian study included 560 patients, in which ICBT 
was evaluated both when patients were guided by their primary care practitioner in the 
community or by a specialist clinician as in Studies I-IV. There were similar effect sizes in both 
types of supervision (d = 0.99 – 1.09) which are in the same range as the observed effects in 
Study I (d = 0.86 – 1.15). These are all large treatment effects, comparable to standard CBT 
with an average treatment effect of d = 0.83 (27). The patient satisfaction rate of 80% observed 
in Study I also indicate that ICBT is highly acceptable among those who provided post-
treatment feedback.  
An interesting observation in Study I was the yearly increases in treatment effects. Since these 
could not be explained by baseline clinical and demographic patient characteristics that were 
tested as co-variates, these yearly improvements might be attributed to the accumulation of 
clinical experience in delivering ICBT.  
A final comment on the symptomatic changes observed in Study I was the timing of the 
improvements in co-morbid depressive symptoms. As can be seen in Figure 3, there was a 
slight left shift relative to improvements in SAD symptoms, suggesting that depressive mood 
is perhaps affected faster than changes in socially avoidant behaviour. The reverse is usually 
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observed in the treatment of depression, where mood tends to improve at a slower rate than the 
psychomotor retardation (98).  
4.1.2 Beneficial effects are maintained 
Both Studies II and III demonstrated that treatment effects achieved after ICBT may be 
sustained for up to four years, not only in regard to symptoms of SAD but also co-morbid 
depressive symptoms and health-related quality of life. The long-term effect size of d = 1.2 
observed in Study II is very similar to that observed in previous follow-up trials with effects of 
d = 1.3 at 2.5 years post-treatment (60) and d = 1.3 after 5 years (59) after treatment. To my 
knowledge, Study II was the first long-term follow-up study of ICBT for SAD when provided 
as routine psychiatric care. As such, it provides evidence of the sustainability of ICBT for SAD 
in clinical practice. 
4.1.3 ICBT is as long-term effective and cost-effective as standard treatment 
In Study III, long-term effects of ICBT were evaluated against standard treatment. Results 
showed that ICBT had a large treatment effect and that the differences between the two 
interventions were within the non-inferiority margin. The results are in line with previous 
empirical findings investigating the long-term effects of ICBT for SAD, where outcome was 
measured at 30 months (60) and 5 years (59) after treatment, with effect sizes of d = 1.30 and 
1.34, respectively. I therefore conclude that ICBT is at least as long-term effective as standard 
treatment for SAD. In addition, patients in both treatments achieved moderate improvements 
in co-morbid depressive symptoms.  
In a recent systematic review of economic evaluations of internet interventions (99), it was 
concluded that for most conditions, internet interventions seem to have a “favourable 
probability” of being more cost-effective than control conditions. In Study III, however, this 
favourable probability appeared to decrease in proportion to the timeframe being considered; 
although the intervention costs for ICBT amounted to only 17% of the costs of standard 
treatment ($464/patient vs $2 687/patient), both treatments resulted in similar long-term 
reductions in overall societal costs. In both interventions, lowered costs related to 
unemployment were the main drivers of these societal gains. As such, treatment of SAD mainly 
seems to affect indirect costs. Indeed, at baseline, the proportion of indirect costs was as high 
as 86% of total costs.xiii This may be compared with the observations in a recent study where 
indirect costs of SAD amounted to 77% of total costs (90). Thus, it appears that the costs 
associated with SAD are first and foremost caused by lower productivity and work loss rather 
                                                 
xiii Baseline total costs for participants in the ICBT condition was estimated at $14 096. Of these, $12 118 were 
indirect costs (unemployment, sick leave, work cutback and domestic). The ratio of indirect costs to total costs can 
therefore be calculated as $12 118 / $14 096 = 86%.  
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than healthcare utilization, an observation that also seems to be congruent with the relatively 
low treatment seeking behaviour observed within this group.  
A second conclusion from Study III, therefore, is that ICBT is at least as long-term cost-
effective as standard treatment as both interventions lead to large improvements in social 
anxiety while reducing societal costs. Considering that ICBT enables each therapist to have up 
to 4 times as many patients in treatment simultaneously compared to standard treatment, I also 
conclude that ICBT is a good option for increasing treatment accessibility. 
4.1.4 ICBT may be suitable also for those with more severe social anxiety 
As was discussed in Chapter 1, the evidence regarding illness severity and its relation to 
treatment outcome has been relatively inconclusive. For example, a review (64) on outcome 
predictors for conventional CBT in the treatment of SAD reported that higher baseline severity 
predicted a higher end state of social anxiety (which was also observed in Study II), but 
concluded that illness severity was not associated with the degree of improvement. Results 
from Study II (Figure 7) suggest that the greater symptom severity before treatment, the higher 
the end state but also the steeper the improvement trajectory. A similar pattern has also been 
observed elsewhere where 2049 patients were treated with ICBT for anxiety and depression 
(100). Thus – and perhaps contrary to common beliefs regarding internet-delivered therapies – 
ICBT seems to work well in terms of symptomatic improvement also for patients who are more 
severely ill, although these patients may be less likely to achieve actual remission from SAD 
(which has also recently been observed elsewhere (69)). It might even be the case that the 
internet-based format of ICBT is particularly suitable for patients with social anxiety who 
might otherwise refrain from seeking care. However, we need to exercise caution when making 
treatment recommendations based on illness severity, considering recent findings showing that 
having a combination of high social avoidance (which constitutes one of the two LSAS 
subscales measuring illness severity) and high co-morbid depressive symptoms significantly 
increases the risk for poor treatment response (69).    
Figure 7. Predicted long-term improvement based on illness severity. Abbreviation: LSAS-SR, Liebowitz Social 
Anxiety Scale-Self-report. 
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4.1.5 Adherence predicts improvement 
As has been established above, ICBT is clinically effective in the treatment of SAD. Based on 
the additional findings of Study IV, it can also be concluded that to benefit from ICBT, patients 
are recommended to comply with the treatment as prescribed. There are additional accounts in 
the literature where a similar association between adherence – either to face-to-face CBT or to 
ICBT – and treatment outcome has been observed (52, 67, 68, 70, 71). To complement the 
illustration of the effect of adherence on improvement as depicted in Fig. 2 in the published 
article of Study IV, I have also made a sub-group analysis using the data set from Study II (N 
= 654) in which patients have been categorized by those who completed all modules and those 
who did not, respectively. A significant difference in improvement rates could be observed 
(Figure 8) where completers (n = 243) evidenced a large pre-post effect size of d = 0.99, 95% 
CI (0.86,1.12) whereas non-completers (n = 301) achieved only about half of that effect; d = 
0.55, 95% CI (0.46, 0.65). 
 
 
Figure 8. Change trajectories of completers vs non-completers. Abbreviation: LSAS-SR, Liebowitz Social Anxiety 
Scale-Self-report. 
 
Since large variations in the level of adherence between patients were observed, and 
consequently variations in how much they benefit from the treatment, future research may 
focus on investigating strategies that may maximise adherence. This may be especially 
important in unguided version of ICBT where the level of adherence is often lower than when 
guided by a clinician (42, 101).  
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4.1.6 Treatment credibility is related to improvement and adherence 
Evidence from Study IV and from previous observations (67, 68) suggests that the perceived 
credibility of the intervention is important for achieving a positive result. Since it was also 
found that credibility was strongly associated with the level of adherence, it may be the case 
that expecting that the treatment will be helpful is an important prerequisite for engaging in the 
treatment, consequently increasing exposure to effective CBT components. Interestingly, it has 
been observed elsewhere that having a pre-treatment interview in itself seems to improve 
treatment adherence (102). It is therefore possible that the diagnostic interviews that were 
conducted at the Internet Psychiatric Clinic prior to treatment could have had an influence on 
the perceived credibility of ICBT, consequently having had a positive effect on motivating 
patients to engage in the treatment. Confronting feared situations is difficult for anyone, but 
confidence in a method might have helped patients to feel more comfortable in going against 
many of the thoughts and feelings that were maintaining the disorder. It is also possible that 
the level of treatment credibility might have been related to the degree of early response as 
credibility was not measured until the second week of treatment. As a result, it is difficult to 
say for certain how patients would have rated treatment credibility prior to or during the initial 
diagnostic clinical meeting (hence being more useful as a prognostic indicator). The relation 
between early response and outcome of ICBT has been examined in a recent study (103) 
although symptomatic measurement at week four was then found to be the optimal occasion to 
predict outcome. 
4.2 IMPLICATIONS FOR PUBLIC SECTOR POLICY AND PRACTICE 
The collective evidence presented within this thesis may have a number of implications for 
public mental healthcare and practice. These will be discussed below, and mainly concern the 
following areas: 
 National dissemination of ICBT 
 Allocation of therapist resources 
 Assuring and improving the quality of care 
4.2.1 National dissemination of ICBT 
As Swedish policy makers recognise the need for management and prevention of mental illness 
and the implications for the labour market, national dissemination of effective and resource-
efficient treatments such as ICBT is hopefully becoming recognised as a viable option with 
potential to meet the growing need for treating mental disorders. E-health is now a central part 
of the healthcare strategy among Swedish municipalities, county councils and regions as a 
means to increase quality, to achieve a more equitable care and to use healthcare resources 
more efficiently. A promising initiative that has been undertaken is the current development of 
a national IT platform (Internetbaserat stöd och behandling) for internet-based support and 
treatment, intended for use by healthcare staff and patients within the public healthcare. Several 
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county councils have already expressed interest in participating in a collaborative effort to offer 
ICBT for its community members. As a first step, a plan for dissemination and development of 
ICBT may therefore include a nation-wide implementation of those treatments that, to date, 
have been clinically evaluated in routine care, e.g. the treatment for SAD evaluated in Studies 
I-IV and treatments for depression and panic disorder (104, 105). Ideally, ICBT providers 
should aim to report key outcome measures to a national quality registry for internet 
interventions as this would allow for easy identification of best practice through outcome 
comparisons between clinics, thereby stimulating learning and continuous quality 
improvements. Such a register (Svenska internetbehandlingsregistret, SibeR) is currently under 
development with a pilot implementation initiated during 2015.  
4.2.2 Allocation of therapist resources 
A second aspect concerns the optimal use of trained therapists as they are in limited supply. I 
believe that the two following circumstances render it likely that therapists will have a more 
supervisory role in the future rather than that of directly treating patients: 
1. We are in the middle of an e-learning paradigm shift in which teaching and learning is 
increasingly conducted online (106). 
2. A growing body of research indicate that self-guided internet-based treatments 
(optimally coupled with intelligently designed automated feedback) may yield results 
comparable to therapist-guided treatments (43, 44, 48-53, 55, 56, 59, 60, 107-111).   
Hence, the trend of e-health and internet-based interventions within mental healthcare points 
towards an increasing standardisation and automation, as such increasing the distance between 
patients and therapists similar to that of students and teachers within the educational system 
through online distance learning. This is a logical consequence of having limited human 
resources (therapists/teachers) while providing services (treatments/courses) to an increasing 
number of individuals in need of these services. From a utilitarian perspective, this 
development might be considered as good since it strives to maximise the utility and well-being 
of the population by allowing more people to access effective care. Still, the role of the therapist 
is an ongoing debate, where some argue that therapist support is necessary for achieving 
acceptable treatment gains (112) based on evidence of poor response when guidance is not 
provided (58). We also observed in Study IV that therapist time was negatively associated with 
the speed of recovery. This may suggest that patients who have difficulties are also in need of 
more specialised therapist support throughout treatment and that less active patients may 
require therapists to invest more time to motivate patients. Then again, there is evidence that 
finds no support for the assumption that guidance from a therapist is necessary for 
improvement; for example, an interesting finding was that adding live exposure sessions to an 
ICBT treatment did nothing to improve the outcome (54). On the whole, it seems that, at least 
for some patients, therapist guidance in ICBT may not be as necessary for achieving a treatment 
response as we might have assumed. Indeed, in a recent review covering 37 RCTs, it was 
concluded that guidance may not be required to achieve immediate gains through ICBT, 
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although guidance and support may help maximize treatment adherence (113). It was also 
noted that the clinical experience of the person providing support does not seem to have any 
effect on treatment success.  
Since therapist support may be needed for some but not all patients, if follows that limited 
therapist resources should optimally be allocated where it is needed the most, possibly through 
some selection criteria. An example of this line of reasoning is the application of a stepped care 
approach (39). In Figure 9, I provide an example of how treatment delivery could be configured 
based on the amount of support needed. The benefits, costs and potential drawbacks of such an 
approach should, of course, have to be evaluated. In addition, criteria for allocating patients 
between steps have to be determined.  
 
I am aware of two studies in which a stepped care approach to ICBT for SAD has been 
previously investigated. In the first study, Berger and colleagues (48) compared three types of 
support within a randomised controlled trial. In one of the treatment arms, the level of therapist 
support was flexible and stepped up as demanded by the patients. Interestingly, there were no 
significant differences between treatment conditions, neither in terms of improvements in 
symptoms of SAD nor in treatment adherence; patients in all treatment arms achieved large 
improvements with a mean effect size of d = 1.47. In the second study, recently published by 
Haug and colleagues (114), a stepped care approach including psychoeducation, ICBT and 
face-to-face CBT was evaluated against standard face-to-face CBT. A purpose of the study was 
to identify moderators of treatment outcome between face-to-face CBT and stepped care, i.e. 
to see if baseline characteristics might indicate whether one treatment approach is more 
beneficial than the other for different subgroups of patients. However, no selection criteria for 
recommending one form of treatment over the other could be defined. Hence, further research 
is needed in order to determine patient factors that may indicate whether high-intensity CBT 
Step 5
Face-to-face
Step 4
Therapist-guided ICBT
Step 3
Self-guided ICBT with feedback from non-specialists
Step 2
Self-guided ICBT with automated feedback
Step 1
Online psychoeducation
Figure 9. A stepped-care approach to internet-based treatments. 
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(e.g. face-to-face CBT) would be more helpful than low-intensity CBT (e.g. unguided or guided 
ICBT).  
4.2.3 Assuring and improving the quality of care 
Within the mental healthcare system, systematic and structured monitoring of processes and 
patient outcomes is needed to assure the quality of care and patient safety. However, current 
electronic medical records and systems are mostly used for administrative purposes. Since 
ICBT was first implemented in regular care, the ICBT unit at Psychiatry Southwest has 
systematically registered the course of illness and treatment outcomes for all treated individuals 
which allows for performance monitoring and continuous assessment of the quality of care. 
The ICBT unit could therefore be considered as an example of a process-based quality 
management system for mental healthcare that can provide a basis for a discussion about best 
practices between caregivers regarding the provision of e-health interventions to treat 
psychiatric disorders. The quality register for internet interventions, SibeR, may further provide 
future transparency in treatment outcomes and quality indicators between healthcare providers. 
Increased awareness of best practices and also differences in clinical practices and outcomes 
may therefore be achieved. Ideally, this would in turn lead to organisational learning and 
continuous improvements in the quality of care and in patient outcomes. 
4.3 LIMITATIONS   
In this section, I will discuss a selected number of potential limitations.  
4.3.1 Controlling for spontaneous recovery 
None of the four studies had a waiting list control group, which makes it difficult to control for 
possible spontaneous improvement and the effect of time. Although a waiting list would have 
been ideal to assure that the observed improvements may be attributed to ICBT, such 
limitations were more or less unavoidable in Studies I, II and IV considering that these were 
retrospective cohort studies aimed at evaluating how ICBT works in a naturalistic setting. Also, 
empirical evidence renders it unlikely that the observed effects can be explained by 
spontaneous recovery, for example:  
 SAD is considered to be a chronic condition if untreated (115); 
 meta-analytic evidence suggest that CBT is more effective than placebo in the treatment of 
anxiety disorders (116); 
 ICBT for SAD is superior to waiting list controls (43, 51, 52, 55, 56, 108); 
 only 13-14% recover from SAD without treatment after one year (117), as opposed to 34% 
who had achieved remission at six-month follow-up in Study I. 
In Figure 10, I have also compared the observed pre-post change after ICBT in routine care 
(Study I) with those reported for several wait-list controls in previous studies; the effect of 
treatment seems evident. 
  25 
  
 
Figure 10. Internet-based cognitive behavioural therapy in routine care compared with wait-list controls. 
Abbreviations: LSAS, Liebowitz Social Anxiety Scale. References: Andersson G, Carlbring P, Holmstrom A, et al. 
Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomised 
controlled trial. Journal of consulting and clinical psychology 2006;74:677-86. Carlbring P, Gunnarsdottir M, 
Hedensjo L, Andersson G, Ekselius L, Furmark T. Treatment of social phobia: randomised trial of internet-
delivered cognitive-behavioural therapy with telephone support. The British journal of psychiatry 2007;190:123-
8. Furmark T, Carlbring P, Hedman E, et al. Guided and unguided self-help for social anxiety disorder: randomised 
controlled trial. The British journal of psychiatry 2009;195:440-7.  
 
4.3.2 Missing data 
Attrition is often an issue in observational studies. Hence, there is a risk that the high degree of 
missing follow-up data in Studies I and II may have led to biased estimates. To address this 
issue, a number of elaborate NMAR xiv analyses were performed in Study I which tested 
different assumptions of the patterns of missing data and its possible consequences for 
inferences and estimates. Since results were generally unaffected by these different 
assumptions, it is unlikely that the observed data loss at follow-up would have significantly 
affected the outcome estimates. However, all estimates should nonetheless be interpreted with 
some degree of caution – after all, statistical models are probabilistic, and therefore inherently 
uncertain. 
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4.3.3 Possibility of response bias in self-report measures 
The reliance on patient-reported outcome measures instead of clinician-rated measures may 
have increased the risk of possible response bias, thereby affecting the validity of the 
measurements. To control for this, the correlation between the self-rated and the clinician rated 
versions of the LSAS was tested to assess their level of agreement. They were found to be 
highly correlated; r(572) = .77, p < .001. I therefore believe that the use of self-reports is a valid 
form of administration. This has also been demonstrated elsewhere (118).  
A similar issue might be considered in regard to the cost-effectiveness analyses in Study III, 
which relied on the self-reported instrument TIC-P for collecting cost data instead of using 
register data; it is possible that this might have influenced the precision of cost-estimation, since 
the estimated costs relied on patients’ recollections of events on which direct and indirect costs 
were calculated. On the other hand, just as for the demonstrated correlation between the LSAS 
and the LSAS-SR, there seems to be a high level of agreement between costs estimated through 
self-assessments and through registry data (119). 
4.3.4 Measurement of adherence and treatment dose received 
The ICBT intervention consists of separate modules, similar to sessions in a live CBT 
intervention. The operational definition of adherence used throughout the studies were the 
number of accessed modules between pre- and post-treatment measurement. However, this 
estimate does not provide precise information regarding the actual treatment dose received, 
since we have no quantified measure of the degree to which patients completed each module. 
However, since this applies to all cases analysed, the relationship between the number of 
modules and treatment outcome should still be the same.  
Another issue concerns the term “adherence” itself. On closer inspection, this term may only 
tell us about the speed of engaging with the treatment content during a defined period of time 
(e.g. the 12-week time period of therapist support). If one were to analyse outcome data beyond 
this timeframe such as in long-term follow-up studies (e.g. Study II), the term “adherence” may 
be problematic, because, supposing that patients, as they are encouraged to do, continue to 
engage with the treatment after post-treatment assessment (albeit unguided), the term 
adherence would no longer be synonymous with the actual treatment dose received, i.e. in total. 
It is reasonable to assume that individuals differ in their pace of learning and in the ability to 
assimilate the program material. As was observed in Study II, patients continue to improve 
after the 12-week mark, which may be indicative of their continued unguided work with the 
rest of the treatment. Hence, patients that were classified as “non-adherent” in the analyses may 
in fact have adhered fully if we were to widen the analytic timeframe – they simply might have 
needed more time to complete the treatment. My reflections in this matter merely concerns the 
underlying assumption and/or operationalization of treatment adherence as a commonly used 
term to measure treatment dose, namely that it is limited to a strict timeframe of therapist 
guidance. An alternative would be to use a term such as “study pace” instead of “adherence”, 
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alluding both to the learning context which ICBT essentially constitutes and to reflect that 
which is actually measured, namely how much of the treatment was accessed during a specified 
period of time. However, such a term would not be without problems either, because some 
patients may for example complete the first three modules in three weeks and then drop out, 
thereby having kept a high pace from one perspective while a low pace from another.  
4.3.5 Generalizability 
Although the relatively large samples in Studies I, II and IV increases the likelihood of 
generalizability of observed results, there are limitations as to which populations these may 
apply to. As for most contemporary research on ICBT, study samples have been predominantly 
from developed countries such as northwestern Europe and Australia. Consequently, results 
may not necessarily generalize to global populations. Therefore, future research should aim to 
replicate these studies in different cultures. As for western populations, the study samples seem 
to be fairly representative of SAD patients in the general population. For example, when 
comparing demographic and clinical characteristics with a large national sample of U.S. adults 
(120), our samples reflects gender differences in prevalence and the age of onset is typically 
around 15 years of age, which reflect our current sample with a mean age of 33 and a mean 
time since debut of first SAD symptoms of 16 years. 
4.4 FURTHER RESEARCH 
4.4.1 Determining optimal resource allocation and utilization 
While ICBT is considered as a cost-effective treatment option (mainly because it requires less 
therapist time on average) determining the most efficient use of therapist resources in the 
delivery of ICBT is an area that may need more attention, given recent empirical evidence 
suggesting that also unguided ICBT can be effective for many patients. For example, in 
Australia, there have been a series of controlled studies testing the efficacy of different versions 
of guided and unguided ICBT (e.g. adding automated emails and SMS reminders) and different 
types and degrees of clinician support (44, 55, 56, 107-110). These interventions are highly 
efficacious in treating SAD, also without therapist guidance. Evidence from independent 
research groups in Switzerland and in Sweden further add to this body of knowledge 
confirming the usefulness of ICBT for SAD, both with and without therapist support, 
demonstrating treatment effects in par with standard treatments (43, 48-53, 59, 60, 111). 
Evaluating the clinical effectiveness of unguided treatments for SAD – especially with 
capabilities of intelligently automated feedback – would therefore be highly interesting, 
drawing inspiration from the Australian research group having developed and implemented 
treatment models with such capabilities (107). Since such interventions would further increase 
the accessibility of effective care, therapist resources providing more individualised support 
could therefore be allocated more selectively to those who need it the most. 
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Another approach to study resource utilization may be to evaluate costs and benefits of a 
standard ICBT clinical pathway from a health care provider’s perspective, meaning that a more 
detailed analysis of the costs and resources needed to deliver care are performed and evaluated 
against produced health outcomes. Such methods would complement CEAs, which are 
typically conducted from a societal perspective, by achieving a more concrete understanding 
of the constituent parts of the whole value chain, from referral to a treated patient. Achieving a 
detailed map of the overall healthcare processes, its sub-processes and activities as well as 
observed patient outcomes, calculated resources used and costs accrued may be essential in 
order to create a system that is capable of continuously monitoring and improving not only the 
quality of care, but also the efficiency of care.  
4.4.2 Prevention and early intervention 
Due to the early onset of SAD and the risk of chronicity, future research should supplement 
existing treatments for adults with internet-based interventions that are aimed at children and 
adolescents. Such early interventions are clearly needed, since approximately 80% of children 
and adolescents in need of help generally do not receive any treatment (121-124). Low 
treatment availability is part of the problem, but this group is also highly reluctant to seek help 
due to stigmatisation and embarrassment, and self-help seems to be the preferred treatment of 
choice (125). Also, given the high level of computer literacy among today’s young generations, 
the advantages of internet interventions might be even more evident. A recent meta-analysis 
on ICBT for youth in the treatment of depression and anxiety reported that internet 
interventions seem to be equally efficacious as face-to-face psychotherapy (126). However, 
there is limited research on early ICBT interventions for SAD specifically; I am only aware of 
one ICBT study aimed at youth, and the results were promising with a large pre-post treatment 
effect size of d = 0.98 (111). There are also few studies on using ICBT for prevention – and 
these are primarily aimed at managing depression (127, 128) – hence this would also be an 
important area for future research on ICBT for SAD. 
4.4.3 Tools for prediction research to increase clinical usability 
In Study IV, outcome predictors of ICBT were explored through the use of multilevel 
modelling. An indication of how different patient and treatment-related characteristics 
influence the rate of improvement during treatment was achieved. For example, treatment 
credibility appeared to have a significant relationship with how patients comply with and 
respond to treatment and a relationship was found between illness severity and the speed of 
symptomatic change. But how can clinicians use such knowledge in their day-to-day practice? 
Perhaps what is needed are more instructive decision rules specifically aimed at providing 
clinical guidance and to facilitate the interpretation of results reported from prediction research 
studies. A typical situation is when making the decision of either including or excluding 
patients to ICBT. One possibility would be the use of decision tree analyses. Easily 
interpretable decision rules and cut-off values would help clinicians make practical use of 
identified outcome predictors. Clinical decisions could then be based on information regarding 
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the probability of, for example, remission or treatment response for different subgroups of 
patients. 
4.5 OVERALL CONCLUSIONS OF THE THESIS 
This research project has demonstrated that: 
 ICBT can be successfully implemented in routine clinical care 
 Beneficial effects are maintained 
 ICBT is as long-term effective and cost-effective as standard treatment 
 ICBT may be suitable also for those with more severe social anxiety  
 Adherence predicts improvement 
 Treatment credibility is related to improvement and adherence 
As an effective and resource-efficient complement to conventional CBT, ICBT may 
significantly increase access to evidence-based care by overcoming several barriers commonly 
associated with conventional face-to-face psychotherapy. Consequently, ICBT may contribute 
to a significant reduction of the societal economic burden of mental illness and provide the 
public healthcare system with effective means to meet the growing need to manage mental ill-
health. 
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